Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) Q1 2026 Earnings Call | 09/12/2025

On September 12, 2025, Kestra Medical Technologies, Ltd. held its Q1 2026 earnings conference call, hosted by Neel Baladkar, Vice President of Investor Relations, with President and CEO Brian Webster and CFO Vasim Mehboob. The call emphasized Kestra’s mission to protect patients at risk of sudden cardiac arrest (SCA) through its Assure Wearable Cardioverter Defibrillator (WCD) system, alongside strong financial performance and strategic growth initiatives.

Key Highlights from CEO Brian Webster

• Mission and Impact: Kestra’s Assure system provides critical heart rhythm monitoring and lifesaving therapy. A case study highlighted a 53-year-old patient saved from SCA by the system’s shock delivery, with patient-triggered ECG recordings enabling timely clinical intervention (e.g., scheduling a cardiac ablation). The Assure Assist service ensured rapid emergency care post-event.

• Market Opportunity: WCD therapy remains underutilized, reaching only 14% of eligible U.S. patients, indicating a multibillion-dollar market potential. A recent German study (SCD PROTECT) underscored the high SCA risk in newly diagnosed heart failure or post-myocardial infarction patients, supporting market expansion.

• Growth Drivers:

  • Sales Expansion: Increased sales territories (from ~80 in FY25) targeting high-WCD-prescription regions with strong in-network payer coverage. An expanded clinical specialist role complements territory managers to deepen account penetration.

  • Revenue Cycle Management (RCM): In-network payer mix rose from 70% at IPO (six months ago) to ~80%, improving efficiency and RCM metrics. Specialized RCM roles (e.g., prior authorization, medical review) enhance collections speed and rate.

  • Device Fleet Investment: The lease-based model supports ~3 patient wears per device annually, with measured fleet expansion to scale with growth.

  • Clinical Evidence: Completed enrollment for an FDA post-approval study (~24,000–25,000 patients), the largest WCD study to date. Results will be presented at the American Heart Association Scientific Sessions in November 2025, focusing on shock success, safety, false alarms, and patient compliance.

Financial Results from CFO Vasim Mehboob

• Q1 2026 Financials:

  • Revenue: $19.4 million, up 52% year-over-year, driven by a 51% increase in Assure system prescriptions (4,200+ written).

  • Gross Margin: 45.7%, up from 32.9% in Q1 2025, marking seven consecutive quarters of expansion. Driven by a 20% decrease in cost per fit (volume leverage) and a 20% increase in adjusted revenue per fit (higher in-network mix).

  • Conversion Rate: Improved to 47% from 40% in Q1 2025, reflecting better prescription fill rates, bid rates, and collections.

  • Operating Expenses: $37.7 million (GAAP), including $2.9 million in non-recurring public company costs; non-GAAP operating expenses at $30.3 million, up due to commercial and RCM investments.

  • Net Loss: $25.8 million (GAAP) vs. $20.3 million in Q1 2025; adjusted EBITDA loss of $19.4 million vs. $15.7 million.

  • Cash Position: $201.2 million as of July 31, 2025, sufficient to reach cash flow breakeven. An additional $15 million term loan tranche is available (undrawn).

• FY 2026 Guidance: Revenue raised to $88 million (+47% year-over-year) from $85 million, driven by continued prescription growth, market share gains, and RCM improvements.

Q&A Highlights

• Guidance Confidence (Travis Steed, BofA Securities): The raised FY26 guidance reflects a strong Q1 and optimism for continued growth, with a steady revenue ramp expected across quarters due to territory manager additions.

• In-Network Mix (Travis Steed, Rick Wise, Stifel): In-network fittings rose to ~80% from 70% at IPO, with a long tail of ~3,000 U.S. payers to contract. Strategic territory expansion targets high-prescription, high-coverage regions, driving gradual increases in revenue per fit and gross margins (targeting 70%+ long-term).

• Prescription Growth (Matthew O’Brien, Piper Sandler): Q1 prescriptions grew ~300 sequentially, driven by improved productivity of existing reps and faster onboarding of new reps. Kestra is capturing ~12% market share, focusing on converting existing accounts and expanding the market.

• Conversion Rate (Lawrence Peterson, Wells Fargo): Guidance assumes a ~2.5% year-over-year conversion rate increase (to ~49.5%), with a long-term goal of high 50s (not 76%). Key drivers include in-network mix, territory expansion, and RCM enhancements.

• Clinical Specialist Role (Mike Pollard, Wolf Research): Expanded clinical specialists support high-performing territories by handling account management, freeing sales reps to pursue new prescribers. This MedTech strategy starts with top accounts to maximize penetration.

• Post-Approval Study (Mike Pollard): The 24,000–25,000-patient study (3-year enrollment) evaluates shock success, safety, false alarms, and compliance. It aims to counter competitors’ claims about Kestra’s clinical data, strengthening its market position.

• Compliance (Daniel Downs, Goldman Sachs): Assure system compliance is strong, with a median daily wear time of >23 hours and sustained adherence over prescription durations, addressing a key WCD utilization barrier.

• OPEX Cadence (Daniel Downs): Investments in territory managers and leadership training will continue steadily, prioritizing high-quality hires to build a durable commercial team.